Biotinylated Human 4-1BB / TNFRSF9 (24-86) Protein, His,Avitag™

ユーザーレビュー
製品番号/仕様
価格
数量
41B-H82E9-25ug
$360.00
41B-H82E9-200ug
$1565.00
ETA of in-stock products:2 business days
総アイテム数 製品金額$ 0

製品詳細

  • Synonyms

    TNFRSF9, 4-1BB, CD137, CDw137, ILA

  • Source

    Biotinylated Human 4-1BB (24-86), His,Avitag (41B-H82E9) is expressed from human 293 cells (HEK293). It contains AA Leu 24 - Cys 86 (Accession # Q07011-1).

    Predicted N-terminus: Leu 24

    Request for sequence
  • Molecular Characterization

    4-1BB Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 10.4 kDa. The protein migrates as 14-16 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

お客様はこちらも閲覧

データ表示

  • SDS-PAGE

    4-1BB SDS-PAGE

    Biotinylated Human 4-1BB (24-86), His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • Bioactivity-ELISA

     4-1BB ELISA

    Immobilized Biotinylated Human 4-1BB (24-86), His,Avitag (Cat. No. 41B-H82E9) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind UreluMab Human IgG4 with a linear range of 0.1-3 ng/mL (QC tested).

    Protocol
  •  4-1BB ELISA

    Immobilized UreluMab Human IgG4 at 1 μg/mL (100 μL/well) can bind Biotinylated Human 4-1BB (24-86), His,Avitag (Cat. No. 41B-H82E9) with a linear range of 1-39 ng/mL (Routinely tested).

    Protocol

ユーザーレビュー
コメントを投稿

バックグランド

4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.

最新の進展

 
医薬品開発の進捗
  • 英語名:

    Tumor necrosis factor receptor superfamily member 9

  • カテゴリ:

  • 市販の医薬品数:

    0 詳細

  • 治験医薬品数:

    77 詳細

  • 最新の開発ステージ:

    Phase 3 Clinical

お問い合わせ
医薬品候補ライセンス
他の関連情報
  • 製品情報
  • 製品詳細
  • お客様はこちらも閲覧
  • データ表示
  • ユーザーレビュー
  • 背景
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8